Prosetta Biosciences, founded in San Francisco, is a biotechnology company dedicated to drug discovery and development. The company's core mission is to create innovative therapeutics for various diseases by identifying and advancing novel small molecules that modulate the assembly of multi-protein complexes within cells. Prosetta offers a range of programs, including antiviral, antibacterial, neuroscience, oncology, and exploratory applications, primarily targeting the US market.
Notable figures associated with Prosetta include leading scientists and industry experts in biotechnology and pharmaceuticals. The company has garnered attention for its significant achievements, such as developing a viral assembly inhibitor that blocks SARS-CoV-2 replication in airway epithelial cells. Prosetta's work has had a substantial impact on the field of drug discovery, contributing to advancements in therapeutic solutions for critical diseases.
